TempraMed
CSE:VIVILive AI agent
TempraMed is a company dedicated to providing innovative solutions for protecting temperature-sensitive medications, particularly insulin and GLP-1 pens.
Investor website: https://tempramed.com/?srsltid=AfmBOop4o8KUeXRXEPQYpDKLl7t-3xVFTxM3xtgC5ELLySDbA0QksRoW
We don’t have processed documents for TempraMed yet, so the AI assistant isn’t available on this page.
About
TempraMed is a company dedicated to providing innovative solutions for protecting temperature-sensitive medications, particularly insulin and GLP-1 pens. Their flagship product, the VIVI Cap, is designed to maintain optimal temperatures for medications in extreme conditions, ensuring safety and efficacy for users. The company is based in Sammamish, Washington, and emphasizes the importance of reliable medication storage for individuals with diabetes and other health conditions.
Verified company data
- Cash position
- not discovered
- Shares outstanding
- 77,669,893
- Fully diluted shares
- 111,495,927
- Mineral resource
- not discovered
- Projects
- ["TempraMed’s recently launched VIVI Cap 1 is an easy-to-use reusable insulin pen cap that keeps diabetes insulin at a safe temperature 24/7 365 days a year, for years on end without need for any user intervention. The product is FDA registered and CE marked. Insulin is a protein that spoils and degrades in the wrong temperature conditions. From the point of manufacturing up until it is used, insulin needs to be kept between 36° to 46°F. During use, insulin does not have to be refrigerated but it should stay below 86°F and should not freeze. Insulin must be protected from such exposure. Injecting insulin that has broken down due to time or temperature, results in poor blood sugar control, and in time can lead to increased dosages and sometimes hospitalization for stabilization. The VIVI Cap 1 shields insulin in-use from potential temperature damage. Thus, reducing the risk of using damaged insulin and wasting money from discarded insulin that might have been compromised. Mr.Ron Nagar, TempraMed CEO and Founder, stated “After spending years recognizing the endless struggle that people with diabetes have to gain control over blood glucose levels, I noticed that those on insulin, take it for granted that insulin is always the same and at its best. But sadly, that is not the reality, so in order to protect the insulin without adding any hassle we developed this unique device and made it available for all.” VIVI Cap uses a unique patented combination of special insulation with “self-regenerating” heat absorbing material and control electronics, this enables the device to operate for years without requiring any user attention or handling. There are no power requirements, no charging and no preliminary preparations needed. For people spending their working days outdoors, there has not been an alternative hassle-free solution that can be used every day to protect insulin from spoiling."]
- Leadership
- Ilan Cohen (Executive Chairman, Serial entrepreneur and Former Director of the Israeli Prime minister's office.), Ron Nagar (Founder and CEO, Medical device serial entrepreneur and inventor. Co-Founder InsuLine Medical and Glucon.), David Ben Naim (Finance Manager, An experienced finance manager of development stage private and public companies.), Daniel Salomon (US Strategic Accounts Advisor, Ex Teva Executive 17 years at Teva. Served as Head of Sales and Marketing for Teva USA institutional business unit.), Gabriel Bitton Ph.D (VP R&D, Medical device development, Simulations, Diabetes and drug delivery expert co-founder InsuLine Medical [TASE : INSL]), Elina Nagar (Co-Founder and COO, Decades of experience in operations and systems for medical devices and Dietician.), Brenda Zeitlin (VP Marketing, More than 25 years of experience in bringing new products to market.), Angelica Khachaturova (VP Business Development, Global Business Development, Strategy, Sales Growth and Marketing, Digital Health and Medical Devices expert.), Gal Cohen (E-commerce Manager, Implementing long-term online marketing strategies for eCommerce brands.), Prof. Andreas Pfutzner M.D. (Medical Director, Managing Director and Founder of PFÜTZNER Science & Health Institute GmbH/ Germany.), Roger Goldman (Board Member, Senior Executive, Public Speaker and Advisor for corporate boards and management teams.), Ran Enoch (Board of Directors, Digital Entrepreneur Executive & Advisor in global online businesses.), Jason Albanese (Board of Directors, Serial entrepreneur Digital Marketing specialist. Strategic planning and business development specialist.), Jennifer L. Carter MD (Board of Directors, Serial entrepreneur and Healthcare Executive. Managing Director at Sandbox Healthcare & The Blue Venture Fund.), Susan Alpert MD, PhD (Chief Regulatory Advisor, Former Director of Device Evaluation at the FDA, Senior VP Global Regulatory affairs at Medtronic.), Brian Hopkins JD (Special Counsel, US IP attorney with over 25 years of experience in intellectual property.), Prof. William V. Tamborlane (Scientific & Medical Advisor, Honored Professor and Chief of Pediatric Endocrinology at Yale School of Medicine.), Dr. Diana Isaacs (Medical Advisor, Endocrine Clinical Pharmacist. 2020 ADCES Diabetes Care & Education Specialist of the Year.), Peter Feinstein M.D (Medical Advisory board, Orthopedic surgeon. Extensive experience in investment and business strategies for interests in and outside the field of medicine.)
Verified data last updated: